Literature DB >> 33801801

Urinary Exosomes Identify Inflammatory Pathways in Vancomycin Associated Acute Kidney Injury.

Linda Awdishu1, Amy Le1, Jordan Amato1, Vidhyut Jani1, Soma Bal2, Robert H Mills1, Marvic Carrillo-Terrazas1, David J Gonzalez1, Ashita Tolwani3, Anjali Acharya4, Jorge Cerda5, Melanie S Joy6,7, Paola Nicoletti8, Etienne Macedo2, Sucheta Vaingankar2, Ravindra Mehta2, Satish P RamachandraRao9.   

Abstract

BACKGROUND: Vancomycin is commonly used as a first line therapy for gram positive organisms such as methicillin resistant Staphylococcusaureus. Vancomycin-induced acute kidney injury (V-AKI) has been reported in up to 43% of patients, especially in those with higher targeted trough concentrations. The precise mechanism of injury in humans remains elusive, with recent evidence directed towards proximal tubule cell apoptosis. In this study, we investigated the protein contents of urinary exosomes in patients with V-AKI to further elucidate biomarkers of mechanisms of injury and potential responses.
METHODS: Urine samples from patients with V-AKI who were enrolled in the DIRECT study and matched healthy controls from the UAB-UCSD O'Brien Center Biorepository were included in the analysis. Exosomes were extracted using solvent exclusion principle and polyethylene glycol induced precipitation. Protein identity and quantification was determined by label-free liquid chromatography mass spectrometry (LC/MS). The mean peak serum creatinine was 3.7 ± 1.4 mg/dL and time to kidney injury was 4.0 ± 3.0 days. At discharge, 90% of patients demonstrated partial recovery; 33% experienced full recovery by day 28. Proteomic analyses on five V-AKI and 7 control samples revealed 2009 proteins in all samples and 251 proteins significantly associated with V-AKI (Pi-score > 1). The top discriminatory proteins were complement C3, complement C4, galectin-3-binding protein, fibrinogen, alpha-2 macroglobulin, immunoglobulin heavy constant mu and serotransferrin.
CONCLUSION: Urinary exosomes reveal up-regulation of inflammatory proteins after nephrotoxic injury in V-AKI. Further studies are necessary in a large patient sample to confirm these findings for elucidation of pathophysiologic mechanisms and validation of potential injury biomarkers.

Entities:  

Keywords:  AKI; complement; exosomes; immune pathways; inflammation; nephrotoxicity; vancomycin

Mesh:

Substances:

Year:  2021        PMID: 33801801      PMCID: PMC7999309          DOI: 10.3390/ijms22062784

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  50 in total

1.  A novel significance score for gene selection and ranking.

Authors:  Yufei Xiao; Tzu-Hung Hsiao; Uthra Suresh; Hung-I Harry Chen; Xiaowu Wu; Steven E Wolf; Yidong Chen
Journal:  Bioinformatics       Date:  2012-02-09       Impact factor: 6.937

Review 2.  Classification, functions, and clinical relevance of extracellular vesicles.

Authors:  Edwin van der Pol; Anita N Böing; Paul Harrison; Augueste Sturk; Rienk Nieuwland
Journal:  Pharmacol Rev       Date:  2012-06-21       Impact factor: 25.468

3.  In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.

Authors:  Faruk Oktem; Meltem Koyuncu Arslan; Fehmi Ozguner; Ozden Candir; H Ramazan Yilmaz; Metin Ciris; Efkan Uz
Journal:  Toxicology       Date:  2005-08-19       Impact factor: 4.221

4.  Optimization and use of peptide mass measurement accuracy in shotgun proteomics.

Authors:  Wilhelm Haas; Brendan K Faherty; Scott A Gerber; Joshua E Elias; Sean A Beausoleil; Corey E Bakalarski; Xue Li; Judit Villén; Steven P Gygi
Journal:  Mol Cell Proteomics       Date:  2006-04-23       Impact factor: 5.911

5.  Quantitative proteomics using reductive dimethylation for stable isotope labeling.

Authors:  Andrew C Tolonen; Wilhelm Haas
Journal:  J Vis Exp       Date:  2014-07-01       Impact factor: 1.355

6.  Up-regulation of galectin-3 in acute renal failure of the rat.

Authors:  J Nishiyama; S Kobayashi; A Ishida; I Nakabayashi; O Tajima; S Miura; M Katayama; H Nogami
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

7.  Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity.

Authors:  Jaya Mishra; Kiyoshi Mori; Qing Ma; Caitlin Kelly; Jonathan Barasch; Prasad Devarajan
Journal:  Am J Nephrol       Date:  2004-05-12       Impact factor: 3.754

Review 8.  Complement regulation in renal disease models.

Authors:  Abhijit Naik; Shweta Sharma; Richard J Quigg
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

9.  Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.

Authors:  Marlies Ostermann; Rinaldo Bellomo; Emmanuel A Burdmann; Kent Doi; Zoltan H Endre; Stuart L Goldstein; Sandra L Kane-Gill; Kathleen D Liu; John R Prowle; Andrew D Shaw; Nattachai Srisawat; Michael Cheung; Michel Jadoul; Wolfgang C Winkelmayer; John A Kellum
Journal:  Kidney Int       Date:  2020-04-26       Impact factor: 10.612

10.  C3a and C5a promote renal ischemia-reperfusion injury.

Authors:  Qi Peng; Ke Li; Lesley A Smyth; Guolan Xing; Naiyin Wang; Lucy Meader; Bao Lu; Steven H Sacks; Wuding Zhou
Journal:  J Am Soc Nephrol       Date:  2012-07-12       Impact factor: 10.121

View more
  3 in total

Review 1.  Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application.

Authors:  Wei-Chih Kan; Yi-Chih Chen; Vin-Cent Wu; Chih-Chung Shiao
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

Review 2.  The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage.

Authors:  Ewa Kwiatkowska; Leszek Domański; Violetta Dziedziejko; Anna Kajdy; Katarzyna Stefańska; Sebastian Kwiatkowski
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

3.  Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients.

Authors:  Jean-Maxime Côté; Michaël Desjardins; Jean-François Cailhier; Patrick T Murray; William Beaubien Souligny
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.